Lastly, the mechanisms underlying the adverse prognostic impact of STK11, KEAP1, and CDKN2A mutations, currently inferred from tumor RNA-seq data and bioinformatic analyses, remain to be experimentally validated in future in vivo and in vitro fundamental research. This evidence concerns the gene CDKN2A and neoplasm.